Cellworks presents breakthrough in predicting chemo-immunotherapy benefit for patients with metastatic NSCLC
Tuesday, September 09, 2025
Cellworks Group has announced findings from the myCare-040 clinical study that highlight the potential of its platform in guiding treatment for patients with metastatic non-small cell lung cancer (NSCLC).
The study, presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona, demonstrated how the Cellworks Platform can predict which patients are most likely to benefit from chemotherapy in combination with immune checkpoint inhibitors (ICIs). The results mark an advance towards a more tailored approach to treatment that can help improve outcomes while reducing unnecessary side effects.
Combination chemo-immunotherapy is currently a standard first-line treatment for advanced NSCLC, but not all patients experience the same benefit. Existing biomarkers such as PD-L1 expression have been widely used to guide treatment, yet remain limited in predicting who will respond well to chemo-immunotherapy.
The Cellworks approach uses next-generation sequencing (NGS) and computational biosimulation to provide patient-specific predictions. By modelling tumour biology and immune system interactions, the platform can distinguish between patients likely to benefit from immunotherapy alone and those who may gain additional benefit from the addition of chemotherapy.
To achieve this, Cellworks developed a mechanistic computational biology model (CBM) that applies tumour-specific genomic data. The model maps signalling pathway disruptions to simulate likely treatment outcomes, offering a more precise way to select therapy for patients with advanced NSCLC.
The findings from myCare-040 suggest that computational modelling could play an important role in refining treatment strategies, improving patient care, and minimising exposure to ineffective or toxic therapies.
Source: businesswire.com
